RHYTHM PHARMACEUTICALS, INC. (RYTM) Earnings
RHYTHM PHARMACEUTICALS, INC.'s most recently reported earnings, recent earnings filings (8-K) and headline annual financials, sourced from SEC EDGAR.
Last reported earnings
Aug 4, 2026
From the latest earnings 8-K
Revenue • FY2025
$189.76M
▲ 45.8%YoY
Diluted EPS • FY2025
$-3.11
▲ 28.3%YoY
Reported earnings dates are based on the latest 8-K (Item 2.02) filings. The next earnings date is an estimate projected from RYTM's historical reporting pattern, not a company-confirmed date.
Headline financials
| Period | Revenue | Net income | Gross profit | Dil. EPS | Free cash flow | Op. margin | Rev. growth |
|---|---|---|---|---|---|---|---|
| FY2025 | $189.76M | -$196.54M | $170.26M | $-3.11 | -$116.63M | -101.2% | +45.8% |
| FY2024 | $130.13M | -$260.6M | $116.76M | $-4.34 | — | -204.0% | +68.1% |
| FY2023 | $77.43M | -$184.68M | $68.13M | $-3.20 | -$136.2M | -238.1% | +227.6% |
| FY2022 | $23.64M | -$181.12M | $21.5M | $-3.47 | -$173.71M | -757.9% | +649.5% |
Recent earnings filings
| Filed | Form | Accession |
|---|---|---|
| Aug 4, 2026 | 8-K (2.02) | 0001628280-26-052170EDGAR |
| May 5, 2026 | 8-K (2.02) | 0001628280-26-030136EDGAR |
| Feb 26, 2026 | 8-K (2.02) | 0001628280-26-011987EDGAR |
| Jan 9, 2026 | 8-K (2.02) | 0001628280-26-001459EDGAR |
| Nov 4, 2025 | 8-K (2.02) | 0001104659-25-105904EDGAR |
| Aug 5, 2025 | 8-K (2.02) | 0001558370-25-010176EDGAR |
| May 7, 2025 | 8-K (2.02) | 0001558370-25-006602EDGAR |
| Feb 26, 2025 | 8-K (2.02) | 0001558370-25-001553EDGAR |
Never miss a RYTM filing.
Get an email when RYTM files its next 8-K, Form 4, 10-K or 10-Q with the SEC. Free, no account needed.
Free foreverNo account requiredOne-click unsubscribe
Data as of Oct 18, 2026Source: SEC EDGAR.